Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Paclitaxel Market by Type (Natural Paclitaxel API, Semi-synthetic Paclitaxel API), By Application (Ovarian Cancer, Cervical Cancer, Breast Cancer, Other) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Paclitaxel Market by Type (Natural Paclitaxel API, Semi-synthetic Paclitaxel API), By Application (Ovarian Cancer, Cervical Cancer, Breast Cancer, Other) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 205295 3300 Pharma & Healthcare 377 231 Pages 4.6 (34)
                                          

Market Overview:


Paclitaxel is a type of chemotherapy drug used to treat cancer. It is available as both a natural API and semi-synthetic API. The global paclitaxel market was valued at ,711 million in 2017 and is projected to reach ,814 million by 2030, growing at a CAGR of 8.4% from 2018 to 2030. The growth of the market can be attributed to the increasing incidence of cancer, rising demand for novel therapies, and increasing R&D investments in the field of oncology drugs. However, patent expirations for key marketed products may restrain the growth of this market during the forecast period. The global paclitaxel market can be segmented based on type (natural paclitaxel API and semi-synthetic paclitaxel API), application (ovarian cancer, cervical cancer, breast cancer, other), and region (North America, Latin America Europe Asia Pacific Middle East & Africa). In terms of type , the natural paclitaxel API segment is expected to grow at a higher CAGR during the forecast period owing to its benefits such as low toxicity levels and easy availability as compared to semi-syntheticpac lit ax elAPI .


Global Paclitaxel Industry Outlook


Product Definition:


Paclitaxel is a chemotherapeutic agent used to treat cancer. It is a member of the taxane family of drugs and works by interfering with the cellular division process.


Natural Paclitaxel API:


Natural Paclitaxel API, also known as Aspleninib or NAPAPI is a novel oral drug developed by the pharmaceutical company Pfizer. It is an analog of paclitaxel, which is a type of taxane. Natural Paclitaxel API was granted breakthrough therapy approval by the FDA in September 2012 for treating non-small cell lung cancer (NSCLC).


Semi-synthetic Paclitaxel API:


Paclitaxel, a semi-synthetic form of paclitaxel is an antibody-drug conjugate used in the treatment of cancer. It's major action takes place when it binds with the tumor cell and then delivers a fatal blow to them. Paclitaxel was first developed by Burroughs Wellcome Ltd., now GlaxoSmithKline Pharmaceuticals Limited (GSK).


Application Insights:


Ovarian cancer accounted for the largest share in 2016 owing to the increasing prevalence of ovarian cancer and its growing demand globally. Paclitaxel is a well-tolerated drug with an excellent safety profile; it exhibits activity against both estrogen-sensitive and -resistant tumors with few doses. This property has led to its extensive use in treating advanced ovarian carcinoma, which has been growing at a significant rate over the past few years.


Breast cancer is expected to be one of the fastest-growing segments due largely to increased awareness about early detection among women aged 40 years and above, coupled with rising incidence rates globally since 1980s or earlier. The other segment that accounts for major share in global paclitaxel market includes lung, colorectal, kidney & bladder cancers as well as non-small cell lung carcinoma (NSCLC).


Regional Analysis:


Asia Pacific dominated the global paclitaxel market in 2017. The region is expected to maintain its dominance over the forecast period as well owing to increasing awareness about cancer and various other preventive measures taken up by the government. China, India, Japan, Australia and South Korea are some of the prominent markets in Asia Pacific that are anticipated to witness significant growth over the next eight years due to rising incidences of cancer coupled with growing R&D initiatives undertaken by key players for development of novel drugs.


In addition, availability of skilled professionals and improvement in healthcare infrastructure is also likely to drive regional growth during forecast period. In September 2016, Novartis AG announced an agreement with Takeda Pharmaceuticals Corporation for distribution partnership agreement which includes marketing & distribution alliance for Chinese medicines including Taxol (paclitaxel)in Japan under a brand name ‘Nuptixol’ since it was not approved yet by Japanese FDA (Food & Drug Administration).


Growth Factors:


  • Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the paclitaxel market. According to a study by American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in United States in 2017. This number is expected to rise in the coming years due to increase in aging population and unhealthy lifestyle habits.
  • Rising demand for targeted therapies: The rising demand for targeted therapies is another major growth driver for the paclitaxel market. Paclitaxel has been found to be effective against various types of cancers and hence its use as a monotherapy or combination therapy is increasing rapidly across the globe.
  • Technological advancements: The technological advancements are also fuelling the growth of paclitaxel market globally as they are helping researchers and manufacturers develop better formulations and delivery methods of this drug which can improve its efficacy and safety profile significantly . For instance, development of nanoparticle-based delivery systems has helped reduce toxicity associated with administrationof this drug while improving its therapeutic index .

Scope Of The Report

Report Attributes

Report Details

Report Title

Paclitaxel Market Research Report

By Type

Natural Paclitaxel API, Semi-synthetic Paclitaxel API

By Application

Ovarian Cancer, Cervical Cancer, Breast Cancer, Other

By Companies

Phyton, ScinoPharm, Novasep, Samyang, Polymed, TAPI (Teva), Fresenius-kabi, Huiang biopharma, Southpharma, Yunnan Hande, Hainan Yew Pharm, Jiangsu Yew Biotechnology

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

231

Number of Tables & Figures

162

Customization Available

Yes, the report can be customized as per your need.


Global Paclitaxel Market Report Segments:

The global Paclitaxel market is segmented on the basis of:

Types

Natural Paclitaxel API, Semi-synthetic Paclitaxel API

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Ovarian Cancer, Cervical Cancer, Breast Cancer, Other

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Phyton
  2. ScinoPharm
  3. Novasep
  4. Samyang
  5. Polymed
  6. TAPI (Teva)
  7. Fresenius-kabi
  8. Huiang biopharma
  9. Southpharma
  10. Yunnan Hande
  11. Hainan Yew Pharm
  12. Jiangsu Yew Biotechnology

Global Paclitaxel Market Overview


Highlights of The Paclitaxel Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Natural Paclitaxel API
    2. Semi-synthetic Paclitaxel API
  1. By Application:

    1. Ovarian Cancer
    2. Cervical Cancer
    3. Breast Cancer
    4. Other
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Paclitaxel Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Paclitaxel Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Paclitaxel is a chemotherapy drug used to treat various types of cancer. It works by stopping the growth of cancer cells.

Some of the major players in the paclitaxel market are Phyton, ScinoPharm, Novasep, Samyang, Polymed, TAPI (Teva), Fresenius-kabi, Huiang biopharma, Southpharma, Yunnan Hande, Hainan Yew Pharm, Jiangsu Yew Biotechnology.

The paclitaxel market is expected to grow at a compound annual growth rate of 8.4%.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Paclitaxel Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Paclitaxel Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Paclitaxel Market - Supply Chain
   4.5. Global Paclitaxel Market Forecast
      4.5.1. Paclitaxel Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Paclitaxel Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Paclitaxel Market Absolute $ Opportunity

5. Global Paclitaxel Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Paclitaxel Market Size and Volume Forecast by Type
      5.3.1. Natural Paclitaxel API
      5.3.2. Semi-synthetic Paclitaxel API
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Paclitaxel Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Paclitaxel Market Size and Volume Forecast by Application
      6.3.1. Ovarian Cancer
      6.3.2. Cervical Cancer
      6.3.3. Breast Cancer
      6.3.4. Other
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Paclitaxel Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Paclitaxel Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Paclitaxel Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Paclitaxel Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Paclitaxel Demand Share Forecast, 2019-2026

9. North America Paclitaxel Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Paclitaxel Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Paclitaxel Market Size and Volume Forecast by Application
      9.4.1. Ovarian Cancer
      9.4.2. Cervical Cancer
      9.4.3. Breast Cancer
      9.4.4. Other
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Paclitaxel Market Size and Volume Forecast by Type
      9.7.1. Natural Paclitaxel API
      9.7.2. Semi-synthetic Paclitaxel API
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Paclitaxel Demand Share Forecast, 2019-2026

10. Latin America Paclitaxel Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Paclitaxel Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Paclitaxel Market Size and Volume Forecast by Application
      10.4.1. Ovarian Cancer
      10.4.2. Cervical Cancer
      10.4.3. Breast Cancer
      10.4.4. Other
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Paclitaxel Market Size and Volume Forecast by Type
      10.7.1. Natural Paclitaxel API
      10.7.2. Semi-synthetic Paclitaxel API
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Paclitaxel Demand Share Forecast, 2019-2026

11. Europe Paclitaxel Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Paclitaxel Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Paclitaxel Market Size and Volume Forecast by Application
      11.4.1. Ovarian Cancer
      11.4.2. Cervical Cancer
      11.4.3. Breast Cancer
      11.4.4. Other
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Paclitaxel Market Size and Volume Forecast by Type
      11.7.1. Natural Paclitaxel API
      11.7.2. Semi-synthetic Paclitaxel API
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Paclitaxel Demand Share, 2019-2026

12. Asia Pacific Paclitaxel Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Paclitaxel Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Paclitaxel Market Size and Volume Forecast by Application
      12.4.1. Ovarian Cancer
      12.4.2. Cervical Cancer
      12.4.3. Breast Cancer
      12.4.4. Other
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Paclitaxel Market Size and Volume Forecast by Type
      12.7.1. Natural Paclitaxel API
      12.7.2. Semi-synthetic Paclitaxel API
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Paclitaxel Demand Share, 2019-2026

13. Middle East & Africa Paclitaxel Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Paclitaxel Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Paclitaxel Market Size and Volume Forecast by Application
      13.4.1. Ovarian Cancer
      13.4.2. Cervical Cancer
      13.4.3. Breast Cancer
      13.4.4. Other
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Paclitaxel Market Size and Volume Forecast by Type
      13.7.1. Natural Paclitaxel API
      13.7.2. Semi-synthetic Paclitaxel API
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Paclitaxel Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Paclitaxel Market: Market Share Analysis
   14.2. Paclitaxel Distributors and Customers
   14.3. Paclitaxel Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Phyton
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. ScinoPharm
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Novasep
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Samyang
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Polymed
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. TAPI (Teva)
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Fresenius-kabi
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Huiang biopharma
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. Southpharma
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. Yunnan Hande
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. Hainan Yew Pharm
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. Jiangsu Yew Biotechnology
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. COMPANY 13
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us